Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2012 Mar;53(3):239-43.
doi: 10.1016/j.jcv.2011.12.009. Epub 2011 Dec 30.

Evidence of immune memory 8.5 years following administration of a prophylactic human papillomavirus type 16 vaccine

Ali Rowhani-Rahbar  1 , Frances B Alvarez, Janine T Bryan, James P Hughes, Stephen E Hawes, Noel S Weiss, Laura A Koutsky
Affiliations
Randomized Controlled Trial

Evidence of immune memory 8.5 years following administration of a prophylactic human papillomavirus type 16 vaccine

Ali Rowhani-Rahbar et al. J Clin Virol. 2012 Mar.

Abstract

Background: The duration of protection conferred by prophylactic human papillomavirus (HPV) L1 virus-like particle vaccines is a critical determinant of their public health impact. A feature of vaccines that confer long-term immunity is their ability to induce immune memory.

Objectives: We evaluated antibody responses against HPV types 6, 11, 16 and 18 following administration of the quadrivalent HPV-6/11/16/18 vaccine to women who had previously received a monovalent HPV-16 vaccine.

Study design: As part of an extended follow-up study conducted between 2006 and 2009 in Seattle, Washington, we administered the quadrivalent HPV-6/11/16/18 vaccine to 52 women (19 vaccine and 33 placebo recipients) who had participated in a monovalent HPV-16 vaccine trial 8.5 years earlier. Serum samples were tested for anti-HPV antibodies using competitive Luminex immunoassay.

Results: Following administration of the first dose of the quadrivalent HPV-6/11/16/18 vaccine, the anti-HPV-16 geometric mean titer among monovalent HPV-16 vaccine recipients (GMT=5024.0 milli-Merck units per milliliter [mMU/mL]; 95% confidence interval [CI]: 2710.1, 9313.6 mMU/mL) substantially exceeded that among the placebo recipients (GMT=136.1; 95% CI: 78.5, 235.8 mMU/mL; p<0.01) and their own highest anti-HPV-16 response observed during the original trial (GMT at month 7 of the original trial=1552.7 mMU/mL; 95% CI: 1072.6, 2247.7 mMU/mL; p<0.01).

Conclusions: The findings suggest that the administration of the three-dose regimen of the monovalent HPV-16 vaccine had produced memory lymphocytes, characterized by a heightened immune response following administration of the quadrivalent HPV-6/11/16/18 vaccine that effectively served as an antigen challenge.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

The University of Washington has received funding from Merck & Co., Inc. to support HPV vaccine studies conducted by L.A.K. F.B.A. and J.T.B. were employees of Merck & Co., Inc. at the time of the conduct of the study.

Figures

Figure 1
Figure 1
Flow chart of the study population
Figure 2
Figure 2
Antibody responses against HPV type 6, 11, 16, and 18 following administration of the quadrivalent HPV-6/11/16/18 vaccine to women who had participated in the monovalent HPV-16 vaccine trial. The pre-dose 1 visit refers to the last visit before administration of the first dose of the quadrivalent vaccine or the visit during which the first dose of this vaccine was administered before blood draw, whichever came last. The post-dose 1 visit refers to the visit following administration of the first and before administration of the second dose of the quadrivalent vaccine.
See this image and copyright information in PMC

References

    1. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915–27. - PubMed
    1. Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, Wiley DJ, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol. 2006;107:18–27. - PubMed
    1. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374:301–14. - PubMed
    1. De Carvalho NS, Roteli-Martins CM, Teieira J, Nahud P. Immunogenicity and safety of HPV-16/18 ASO4-adjuvanted vaccine up to 7.3 years. Presented at the 25th International Papillomavirus Conference; Malmö, Sweden. 8 – 14 May 2009.
    1. Rowhani-Rahbar A, Mao C, Hughes JP, Alvarez FB, Bryan JT, Hawes SE, et al. Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine. Vaccine. 2009;27:5612–9. - PMC - PubMed

Publication types

MeSH terms

Substances